Eurocor
Eurocor Tech is a rapidly growing European Life Sciences Technology corporation specializing in the research, development, and manufacture of interventional cardiovascular and endovascular treatment devices made in Europe for the world. With over 20 years of experience, Eurocor provides healthcare solutions across more than 60 countries, focusing on minimally invasive device innovations of outstanding quality to improve and extend life. The company emphasizes safety, efficacy, continuous quality improvement, ecological sustainability, and fostering research, positioning itself as a leader in high-quality minimally invasive medical technology.
Industries
Nr. of Employees
small (1-50)
Products
Paclitaxel-eluting peripheral drug-coated balloon catheters
Drug-coated PTA balloon catheters indicated for peripheral arterial interventions to deliver paclitaxel locally and avoid permanent implants.
Paclitaxel-eluting coronary drug-coated balloon catheters
Rapid-exchange balloon catheters for coronary applications, formulated to deliver paclitaxel locally (stentless therapy option) with coating designed to minimize systemic exposure.
High-pressure paclitaxel-eluting balloons for arteriovenous (AV) shunt interventions
High-rated-burst-pressure balloon catheters designed for dilation of stenoses in AV fistulas and grafts in dialysis patients with drug coating to prolong patency.
Sirolimus-eluting coronary stent systems with polymer-controlled release
Coated cobalt-chromium stent systems designed for coronary lesion treatment using a polymer coating to control sirolimus release and promote polymer resorption over weeks.
Peripheral plain (uncoated) pre-dilatation balloon catheters
Non-drug-coated PTA balloon catheters intended for vessel preparation, pre-dilatation and standard plain-old balloon angioplasty (POBA) procedures.
Paclitaxel-eluting peripheral drug-coated balloon catheters
Drug-coated PTA balloon catheters indicated for peripheral arterial interventions to deliver paclitaxel locally and avoid permanent implants.
Paclitaxel-eluting coronary drug-coated balloon catheters
Rapid-exchange balloon catheters for coronary applications, formulated to deliver paclitaxel locally (stentless therapy option) with coating designed to minimize systemic exposure.
High-pressure paclitaxel-eluting balloons for arteriovenous (AV) shunt interventions
High-rated-burst-pressure balloon catheters designed for dilation of stenoses in AV fistulas and grafts in dialysis patients with drug coating to prolong patency.
Sirolimus-eluting coronary stent systems with polymer-controlled release
Coated cobalt-chromium stent systems designed for coronary lesion treatment using a polymer coating to control sirolimus release and promote polymer resorption over weeks.
Peripheral plain (uncoated) pre-dilatation balloon catheters
Non-drug-coated PTA balloon catheters intended for vessel preparation, pre-dilatation and standard plain-old balloon angioplasty (POBA) procedures.
Services
Design and execution of randomized clinical trials and multicenter registries, patient follow-up and outcome reporting for interventional device safety and efficacy.
In vitro cytotoxicity assays and in vivo animal-model studies to assess device biocompatibility, tissue drug retention, neointimal proliferation and lumen preservation.
Development and application of amorphous and polymer-based coatings for controlled local drug delivery from balloons and stents, including evaluation of wash-off and transfer characteristics.
Design and execution of randomized clinical trials and multicenter registries, patient follow-up and outcome reporting for interventional device safety and efficacy.
In vitro cytotoxicity assays and in vivo animal-model studies to assess device biocompatibility, tissue drug retention, neointimal proliferation and lumen preservation.
Development and application of amorphous and polymer-based coatings for controlled local drug delivery from balloons and stents, including evaluation of wash-off and transfer characteristics.
Expertise Areas
- Interventional device design for coronary and peripheral applications
- Coating development for controlled drug delivery
- Preclinical in vivo and in vitro evaluation
- Clinical trial and registry management
Key Technologies
- Drug-eluting balloon (DEB) technology
- Drug-eluting stent (DES) technology
- Amorphous bioshell and shellac-based coatings
- PLGA 85/15 polymer drug coatings
News & Updates
Eurocor will present its 5-year safety and efficacy data at the LINC 2024 conference in Leipzig, Germany, from June 6-9, 2024.
Eurocor will present its 5-year safety and efficacy data at the IROS 2024 conference in Salzburg, Austria, in December 2023.
Eurocor will present its 5-year safety data at CIRSE 2023 in Copenhagen, with the presentation scheduled for September 12, 2023.
Eurocor announced the CE-marking and commercial launch of Eurolimus™, a Sirolimus eluting coronary stent system, offering high flexibility and overexpansion capabilities with one of the lowest strut thicknesses.
Eurocor will present its 5-year safety and efficacy data at the LINC 2024 conference in Leipzig, Germany, from June 6-9, 2024.
Eurocor will present its 5-year safety and efficacy data at the IROS 2024 conference in Salzburg, Austria, in December 2023.
Eurocor will present its 5-year safety data at CIRSE 2023 in Copenhagen, with the presentation scheduled for September 12, 2023.
Eurocor announced the CE-marking and commercial launch of Eurolimus™, a Sirolimus eluting coronary stent system, offering high flexibility and overexpansion capabilities with one of the lowest strut thicknesses.